ThromboGenics to initiate post-marketing trial of Jetrea

ThromboGenics plans to initiate a U.S. phase 4 study of Jetrea this month, according to a press release. The Ocriplasmin Research to Better Inform Treatment (ORBIT) study will generate more data on the real-world use of Jetrea (ocriplasmin). The prospective, observational study will recruit 1,500 patients with symptomatic vitreomacular adhesion or vitreomacular traction across 120 U.S. retina centers and assess clinical outcomes and safety of Jetrea administered in a real-world setting through anatomical and functional outcomes.

Full Story →